Screener
McKesson MCK Prescription Technology Solutions — Foreign currency translation adjustments, net
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by McKesson in its filing.
Tagged under the XBRL concept us-gaap:GoodwillForeignCurrencyTranslationGainLoss.
The source filing: McKesson’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:29 PM EDT
- Fiscal quarter
- Q1 FY2027
- Calendar quarter
- Q2 2026
- Accession
- 0000927653-26-000234
| (In millions) | North American Pharmaceutical | Oncology & Multispecialty | Prescription Technology Solutions | Medical-Surgical Solutions | Total |
|---|---|---|---|---|---|
| Balance, March 31, 2026 | $2,781 | $3,963 | $2,065 | $2,507 | $11,316 |
| Goodwill acquired | — | 13 | — | — | 13 |
| Disposals | — | (2) | — | — | (2) |
| Foreign currency translation adjustments, net | (26) | — | — | — | (26) |
| Other adjustments (1) | — | (23) | — | — | (23) |
| Balance, June 30, 2026 | $2,755 | $3,951 | $2,065 | $2,507 | $11,278 |
Item 1. Condensed Consolidated Financial Statements.
FAQ
- What is McKesson's prescription technology solutions — foreign currency translation adjustments, net?
- McKesson (MCK) reported prescription technology solutions — foreign currency translation adjustments, net of $0 in Q2 2026.
- What does prescription technology solutions — foreign currency translation adjustments, net mean?
- This metric captures the net impact of foreign currency exchange rate fluctuations on the financial results of the Prescription Technology Solutions segment. It reflects the translation of international operations' financial statements into the reporting currency. It is a non-cash adjustment that highlights exposure to global market volatility.
Ask your AI about McKesson's prescription technology solutions — foreign currency translation adjustments, net.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude